

20 January 2026

LTIMindtree*Strong execution continues amid near term headwinds; retain BUY*

Despite furloughs, LTIMindtree (LTIM) delivered a solid performance in Q3FY26, with CC revenue rising by 2.4% q/q to \$1.21bn and EBIT margin expanding by 20bps q/q to 16.1% LTIM saw a one-time labour-code impact of Rs5.9bn. LTM TCV came in at \$1.69bn (up 0.6% y/y) with a book-to-bill of 1.4x, while the LTM TCV stood at \$6.5bn (up 12% y/y), driven by multi-year wins across managed services, modernisation, cyber, data, AI and AI-agent deployments, as the clients consolidate spend into fewer strategic partners and fund 'run + modernize' programs alongside targeted AI-led transformation. Whilst the growth was broad-based, it was skewed to Manufacturing & Resources (up 9.4% q/q) and Healthcare & Public Services (up 9.9%), with Europe (up 3.4%) and RoW (up 14.1%), driven by execution and wallet share gain in select pockets. Top 5 client headwinds are largely a productivity-cycle issue that should bottom out by Q4FY26, setting up a more growth-oriented mix. Thus, once that drag fades, vendor consolidation becomes a wallet-share opportunity rather than a risk. We maintain BUY rating on the stock with a revised TP of Rs7,375 (from Rs7,081 earlier), implying a ~16.0% upside from CMP.

Large Deal Win and Execution Intensity – Key Differentiators: LTIM's large deal wins i.e., PAN 2.0, ADM & Paramount deals have organically driven portfolio diversification despite two consecutive quarter of revenue de-growth in Q3 (down 2.9% in Q3 and down 5.4% in Q2) in Top 5 accounts.

Stable Margin Aided by Fit4Future: EBIT margin rose 20bps q/q to 16.1%, despite seasonal furloughs, led by Fit4Future cost action, pyramid optimisation, forex tailwinds and SG&A discipline, partially offset by furloughs.

Outlook & Valuation: At CMP, the stock trades at FY27e/28e P/E of 29.9x/26.2x. We have marginally tweaked our FY26e/27e/28e revenue and EPS estimates by 0.1/0.5%, 0.1/0.7% and 0.7/2.0% respectively. Expecting 14% CAGR in adj. EPS over FY26-28e, we maintain BUY rating on the stock with a revised TP of Rs7,375 (from Rs7,081 earlier), implying a ~16.0% upside from CMP.

Risks: (a) Prolonged slowdown in discretionary IT spending; (b) execution risk in bookings to revenue conversion; (c) continued pain in largest BFSI client.

Key Financials (Y/E Mar)	FY24	FY25	FY26e	FY27e	FY28e
Sales (Rs m)	3,55,170	3,80,081	4,20,273	4,60,861	4,98,115
Net profit (Rs m)	45,821	45,987	51,038	63,124	72,061
Reported EPS (Rs)	155	155	172	213	243
PE (x)	41.2	41.0	37.0	29.9	26.2
EVEBITDA (x)	27.3	26.9	22.9	20.2	18.1
PBV (x)	9.4	8.3	7.4	6.4	5.5
RoE (%)	25.0	21.5	21.1	22.8	22.5
RoCE (%)	20.8	17.3	18.2	18.5	18.3
Dividend yield (%)	1.0	1.0	1.1	1.2	1.4
Net debt/equity (x)	-0.6	-0.6	-0.6	-0.7	-0.7

Source: Company, Anand Rathi Research

Rating: **BUY**


Target Price (12-mth): Rs.7,375

Share Price: Rs.6,360

Key Data	LTIM IN / LRTI.BO
52-week high / low	Rs6430 / 3802
Sensex / Nifty	83246 / 25586
Market cap	Rs1809bn
Shares outstanding	296m

Shareholding (%)	Sep'25	Jun'25	Mar'25
Promoters	68.5	68.6	68.6
- of which, Pledged			
Free float	31.5	31.4	31.4
- Foreign institutions	6.4	6.6	7.0
- Domestic institution	16.6	16.1	15.5
- Public	8.5	8.7	8.9

Estimates Revision (%)	FY26e	FY27e	FY28e
Sales (\$)	0.1	0.1	0.7
Adj. EBIT	-0.1	1.3	4.5
Adj. PAT	0.5	0.7	2.0

Relative Price Performance

Source: Bloomberg

Sushovon Nayak
Research Analyst

Apoorva Khandelwal
Research Associate

Harshita Parakh
Research Associate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Quick Glance – Financial and Valuations (Consolidated)

Fig 1 – Income Statement (Rs m)

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
Revenues (US\$ m)	4,287	4,493	4,774	5,158	5,575
Growth (%)	4.4	4.8	6.3	8.1	8.1
Net revenue (Rs m)	3,55,170	3,80,081	4,20,273	4,60,861	4,98,115
Employee & Direct Costs	2,64,218	2,82,128	3,02,623	3,30,943	3,59,401
Gross Profit	90,952	97,953	1,17,650	1,29,918	1,38,714
Gross Margin (%)	25.61	25.77	27.99	28.19	27.85
SG&A	27,078	33,004	41,308	43,613	42,402
EBITDA	63,874	64,949	76,343	86,305	96,312
EBITDA margins (%)	18.0	17.1	18.2	18.7	19.3
- Depreciation	8,189	9,915	10,588	11,001	11,448
Other income	7,019	9,897	11,998	12,069	13,921
Interest Exp	2,217	2,789	2,803	2,145	1,407
PBT	60,487	62,142	69,047	85,228	97,379
Effective tax rate (%)	24	26	27	26	26
+ Associates/(Minorities)	-25	-33	414	440	440
Net Income	45,821	45,987	51,038	63,124	72,061
WANS	296	296	297	297	297
FDEPS (Rs/share)	155	155	172	213	243

Fig 3 – Cashflow Statement (Rs m)

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
PBT	60,487	62,142	69,047	85,228	97,379
+ Non-cash items	5,940	4,493	10,587	11,001	11,448
Operating profit before WC	66,427	66,635	79,634	96,229	1,08,826
- Incr./(decr.) in WC	-5,975	4,803	4,344	2,581	1,319
Others including taxes	-15,707	-16,374	-18,423	-22,543	-25,757
Operating cash-flow	56,695	45,458	56,867	71,104	81,750
- Capex (tang. + Intang.)	8,330	9,336	9,273	8,785	7,503
Free cash-flow	48,365	36,122	47,595	62,319	74,247
Acquisitions	-59	-75	-	-	-
- Div. (incl. buyback & taxes)	17,753	19,246	21,221	23,343	25,677
+ Equity raised	-	-	-	-	-
+ Debt raised	-866	-399	-	-	-
- Fin Investments	33,305	11,547	22,740	27,288	32,745
- Misc. Items (CFI + CFF)	1,559	2,432	-	-	-
Net cash-flow	-5,177	2,423	3,634	11,688	15,824

Source: Company, Anand Rathi Research

Fig 5 – Price Movement



Source: Bloomberg

Fig 2 – Balance Sheet (Rs m)


Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
Share capital	296	296	296	296	296
Net worth	2,00,172	2,26,983	2,56,800	2,96,581	3,42,965
Total debt (incl. Pref)	407	23	23	23	23
Minority interest	92	132	-282	-722	-1,162
DTL/(Asset)	-2,314	-1,978	-1,978	-1,978	-1,978
Capital employed	1,98,357	2,25,160	2,54,563	2,93,904	3,39,848
Net tangible assets	35,568	39,631	39,316	38,100	35,156
Net Intangible assets	15,078	14,212	13,212	12,212	11,212
Goodwill	6,900	6,900	6,900	6,900	6,900
CWIP (tang. & intang.)	4,669	5,818	5,818	5,818	5,818
Investments (Strategic)	-	-	-	-	-
Investments (Financial)	97,396	1,13,699	1,36,439	1,63,727	1,96,472
Current Assets (ex Cash)	1,02,218	1,10,020	1,18,553	1,26,589	1,33,376
Cash	18,200	20,623	24,257	35,945	51,769
Current Liabilities	74,772	78,843	83,032	88,486	93,954
Working capital	27,446	31,177	35,521	38,103	39,422
Capital deployed	1,98,357	2,25,160	2,54,563	2,93,904	3,39,848

Fig 4 – Ratio Analysis

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
P/E (x)	41.2	41.0	37.0	29.9	26.2
EV/EBITDA (x)	27.3	26.9	22.9	20.2	18.1
EV/sales (x)	4.9	4.6	4.2	3.8	3.5
P/B (x)	9.4	8.3	7.4	6.4	5.5
RoE (%)	25.0	21.5	21.1	22.8	22.5
RoCE (%) - After tax	20.8	17.3	18.2	18.5	18.3
RoIC (%) - After tax	41.0	36.8	41.1	46.6	53.0
DPS (Rs per share)	65.0	65.0	71.5	78.7	86.5
Dividend yield (%)	1.0	1.0	1.1	1.2	1.4
Dividend payout (%) - Inc. DDT	42.0	41.9	41.6	37.0	35.6
Net debt/equity (x)	-0.6	-0.6	-0.6	-0.7	-0.7
Receivables (days)	72	74	73	72	71
Inventory (days)	-	-	-	-	-
Payables (days)	19	18	18	18	19
CFO:PAT%	124	99	112	113	114

Source: Company, Anand Rathi Research

Fig 6 – Quarterly CC Revenue Growth (q/q)



Source: Company

Our Key Takeaways

A Strong Performance Despite Seasonal Weakness

- CC revenue came in at \$1,208mn (up 2.4% q/q and 5.2% y/y) in Q3, aided by deal ramp-ups and partial normalisation after Q2 pass-through adjustments linked to AI-driven productivity benefits.
- EBIT margin improved 20bps q/q to 16.1%, despite seasonal furloughs and holiday-related softness. Margin expansion was driven by Fit4Future cost actions, pyramid optimisation, forex tailwinds and SG&A discipline, partially offset by furloughs.
- Deal traction remained healthy with TCV of \$1.69bn (book-to-bill of 1.4x) and LTM TCV of \$6.5bn (up 12% y/y). LTIM continues to sharpen focus on large, multi-year deals and strategic partnerships.
- A key highlight was a \$155m, 5-year AI-led engagement with a large US insurance and financial services client, covering application management, infrastructure operations, and end-user services.
- SG&A declined ~100bps q/q, aided by Fit4Future productivity improvement and a one-off reversal. The management expects SG&A to remain in 11-11.6% range.
- Fit4Future has delivered ~230bps margin improvement over the past nine months (100bps in Q1 and 80bps in Q2), driven by automation, pyramid correction and reduced overhead. The programme is being replaced by 'New Horizons', which will focus on the next phase of efficiency and operating leverage.
- Wage hikes are planned from Q4FY26 with ~50% implemented in Q4 and the balance spread over subsequent quarters. While margin impact is estimated at ~100bps each in Q4FY26 and Q1FY27, the management expects FY26 margin to improve from FY25 level due to ongoing cost programmes.
- The company recognised a one-time exceptional charge of ~Rs5.9bn (~\$66m) in Q3FY26 relating to implementation of new labour codes.
- With net addition of 1,511 employees, headcount rose to ~87,958 (up 1.7% q/q). Attrition declined to ~13.8% in Q3 from 14.2% in Q2.
- **Guidance:** LTIM expects to exit FY26 at double-digit growth, with order bookings improving further into FY27, aligned with a more supportive demand environment.

Demand Commentary

- BFSI (35.1% of revenue) fell 0.7% q/q due to renewal recalibration and AI-driven productivity pass-through, particularly in large North American accounts. The management emphasised this is transitory, with Q4 likely to mark the bottom, as other BFSI accounts are growing faster, and large clients stabilise post productivity resets.
- BFSI margin improved due to Fit for Future-led actions + pyramid improvement via fresher infusion, better realisation and forex benefit.
- Extending the Q2 trend, revenue from Top 5 clients fell 2.9% q/q, reflecting large clients progressing through AI-led productivity journeys and LTIM does not view the decline as structural. Four out

of five large accounts have already transitioned, and portfolio balancing and wallet-share gains from other clients are likely to offset the time.

- Tech, Media & Communications (22.2% of revenue) was flat q/q, showing sequential stabilisation vs. Q2. LTIM reiterated expectations of H2 recovery, aided by large deal ramp-ups (including Media deals i.e., Paramount) and AI-led transformation demand. Segmental margin is now stabilising with the clients entering to productivity journeys.
- Manufacturing (20.8% of revenue) grew 9.2% q/q, as deals started to ramp up. It is now LTIM's third largest segment after BFSI and TMC, driving double-digit y/y growth.
- HLS & Public Services (6.5% of revenues) grew ~10.9% q/q, driven by project lifecycle-led ramp-ups and showing improving momentum.
- RoW (12.4% of revenue) grew 14.4% q/q, driven by the ramp-up of PAN 2.0 deal. The region is also positioned for growth following the Insight 2.0 win from the Government of India, valued at ~Rs30bn (~\$330m) over 7 years (~1% annual revenue contribution).
- North America (72.8%) and Europe (14.8%) grew by 0.4% q/q and 3.1% q/q, respectively.

Commentary on AI Strategy

- LTIM is seeing evolving client expectations shifting from experimentation to scaled AI execution.
- Blue Verse is emerging as a central pillar with next-gen agentic IT services, industry-specific AI factories and proprietary IP and patents.
- LTIM is re-imagining service lines around AIOps and AI-led delivery, embedding productivity, automation and outcome-based constructs into core contracts rather than positioning AI as a standalone offering.
- Armada.ai and hyperscale partnerships continue to strengthen the ecosystem, supporting faster deal conversion and execution at scale.
- Over 50% of employees are now trained in advanced AI skills, improving delivery leverage and supporting margin resilience.


Quarterly Snapshot

Fig 7 – Quarterly Performance (Rs m)

Y/E Mar	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	q/q (%)	y/y (%)
Revenue (\$ m)	1,069	1,096	1,127	1,139	1,131	1,153	1,180	1,208	2.4	6.1
y/y growth (%)	1.1	3.5	4.8	5.1	5.8	5.2	4.7	6.1		
Revenue (Rs m)	88,929	91,426	94,329	96,609	97,717	98,406	1,03,943	1,07,810	3.7	11.6
Effec. exchange rate	83.2	83.4	83.7	84.8	86.4	85.3	88.1	89.2	1.3	5.2
TCV (\$ m)	1,430	1,400	1,300	1,680	1,600	1,630	1,590	1,690	6.3	0.6
TCV (LTM)	5,640	5,630	5,630	5,810	5,980	6,210	6,500	6,510	0.2	12.0
Employees (EoP)	81,650	81,934	84,438	86,800	84,307	83,889	86,447	87,958	1.7	1.3
Rev. prod. (\$ '000/employee)	13.0	13.4	13.5	13.3	13.2	13.7	13.9	13.9	0.0	4.2
CoR (excl. D&A)	(66,554)	(67,830)	(69,313)	(71,845)	(73,142)	(72,457)	(75,123)	(76,623)	2.0	6.7
As % of revenue	-75	-74	-73	-74	-75	-74	-72	-71		
SG&A	(7,018)	(7,535)	(8,023)	(8,831)	(8,613)	(9,455)	(9,519)	(11,160)	17.2	26.4
As % of revenue.	8	8	9	9	9	10	9	-10		
EBITDA	15,357	16,061	16,993	15,933	15,962	16,494	19,301	20,027	3.8	25.7
EBITDA margin (%)	17.3	17.6	18.0	16.5	16.3	16.8	18.6	18.6	1 bps	208 bps
EBIT	13,087	13,709	14,582	13,289	13,454	14,065	16,481	17,371	5.4	30.7
EBIT margin (%)	14.7	15.0	15.5	13.8	13.8	14.3	15.9	16.1	26 bps	236 bps
Other income (excl. forex)	2,240	2,137	2,238	1,993	2,280	2,630	2,352	2,773	17.9	39.1
Non-recurring / Forex	(164)	134	751	132	232	1,291	652	(501)	-176.8	-479.5
Interest expenses	(680)	(724)	(703)	(689)	(673)	(724)	(693)	(693)	0.0	0.6
PBT	14,483	15,256	16,868	14,725	15,293	17,262	18,792	13,047	-30.6	-11.4
PBT margin (%)	16.3	16.7	17.9	15.2	15.7	17.5	18.1	12.1	-598 bps	-314 bps
Taxes	(3,476)	(3,905)	(4,352)	(3,858)	(4,007)	(4,716)	(4,980)	(3,451)	-30.7	-10.5
ETR (%)	-24	-26	-26	-26	-26	-27	-27	-26	5 bps	-25 bps
Minority interest/Income from associates	(8)	(13)	(6)	(13)	(1)	(5)	199	110	-44.7	-946.2
Net income	10,999	11,338	12,510	10,854	11,285	12,541	14,011	9,706	-30.7	-10.6
Net margin (%)	12.4	12.4	13.3	11.2	11.5	12.7	13.5	9.0	-448 bps	-223 bps
EPS (Rs)	37.1	38.2	42.2	36.6	38.0	42.3	47.2	32.7	-30.7	-10.6


Source: Company

Fig 8 – Quarterly CC Revenue Growth (y/y) (%)



Source: Company, Anand Rathi Research

Fig 9 – EBIT Margin (%)



Source: Company, Anand Rathi Research

Valuation

At CMP, the stock trades at FY27e/28e P/E of 29.9x/26.2x. We have marginally tweaked our FY26e/27e/28e revenue and EPS estimates by 0.1/0.5%, 0.1/0.7% and 0.7/2.0% respectively. Expecting 14% CAGR in adj. EPS over FY26-28e, we maintain BUY rating on the stock with a revised TP of Rs7,375 (from Rs7,081 earlier), implying a ~16.0% upside from CMP.

Fig 10 – Change in Estimates

(Rs m)	FY26e			FY27e			FY28e		
	New	Old	Change (%)	New	Old	Change (%)	New	Old	Change (%)
Revenue (\$m)	4,774	4,768	0.1	5,158	5,151	0.1	5,575	5,538	0.7
Revenue (Rs.m)	4,20,273	4,19,336	0.2	4,60,861	4,59,196	0.4	4,98,115	4,93,660	0.9
EBITDA	76,343	76,786	(0.6)	86,305	86,139	0.2	96,312	93,499	3.0
EBITDA Margin (%)	18.2%	18.3%	-15 bps	18.7%	18.8%	-3 bps	19.3%	18.9%	40 bps
EBIT	65,755	65,812	(0.1)	75,304	74,342	1.3	84,864	81,223	4.5
EBIT Margin (%)	15.6%	15.7%	-5 bps	16.3%	16.2%	15 bps	17.0%	16.5%	58 bps
PBT (Adj.)	74,950	74,189	1.0	85,227	83,608	1.9	97,378	94,299	3.3
Net PAT (Adj.)	55,455	55,189	0.5	63,124	62,708	0.7	72,061	70,625	2.0

Source: Anand Rath Research

Fig 11 – 1-Year Fwd. PE



Source: Bloomberg, Anand Rath Research

Risks

- A prolonged slowdown in discretionary IT spending.
- Execution risk in bookings to revenue conversion.
- Continued pain in largest BFSI client.


Appendix

Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies

Rating and Target Price History (as of 20 January 2026)



Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps, Mid Caps & Small Caps as described in the Ratings Table below:

Ratings Guide (12 months)

	Buy	Hold	Sell
Large Caps (Top 100 companies)	>15%	0-15%	<0%
Mid Caps (101st-250th company)	>20%	0-20%	<0%
Small Caps (251st company onwards)	>25%	0-25%	<0%

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015, BSE Enlistment Number – 5048 date of Regn 25 July 2024) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd (BSE), National Stock Exchange of India Ltd. (NSEIL), Multi Commodity Exchange of India Limited (MCX), National Commodity & Derivatives Exchange Limited (NCDEX), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. (CDSL), ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. ARSSBL does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding taxation aspects of any potential investment.

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No
ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	No

NOTICE TO US INVESTORS:

This research report is the product of Anand Rathi Share and Stock Brokers Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated person(s) of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances, and trading securities held by a research analyst account.

Research reports are intended for distribution only to Major U.S. Institutional Investors as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act of 1934 (the Exchange Act) and interpretations thereof by the U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this research report is not a Major U.S. Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated, and/or transmitted onward to any U.S. person which is not a Major U.S. Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major U.S. Institutional Investors, Anand Rathi Share and Stock Brokers Limited has entered into a Strategic Partnership and chaperoning agreement with a U.S. registered broker-dealer: Banc Trust Securities USA. Transactions in securities discussed in this research report should be affected through Banc Trust Securities USA.

1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

© 2026. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

As of the publication of this report, ARSSBL does not make a market in the subject securities.

Registration granted by SEBI, Enlistment as RA and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Additional information on recommended securities/instruments is available on request.

Compliance officer: Deepak Kedia, email id: deepakkedia@rathi.com, Contact no. +91 22 6281 7000
Grievance officer: Madhu Jain, email id: grievance@rathi.com, Contact no. +91 22 6281 7191

ARSSBL registered address: Express Zone, A Wing, 10th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.
Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.